entertainment -WSS

entertainment

author：knowledge 2025-10-01 15:30:55 - browse：26439

Biogen, a biotech giant plagued by years of boardroom strife, said late Monday that the longtime and polarizing director Alex Denner would step down from its board, sending a signal to investors that the company’s fractious recent history might be coming to a close.

What Biogen didn’t disclose is that its nominee to replace Denner on the board, Susan Langer, is Denner’s live-in romantic partner and the mother of his child, born in November, according to court records obtained by STAT. Denner is in the middle of a protracted divorce from his wife of nearly 25 years, with whom he has two teenage sons — a bitter legal fight in which his extramarital relationship with Langer is a contentious issue, according to the records.

Biogen spokesperson Jack Cox said the company knew about the relationship between Denner and Langer. He also said that Denner recommended Langer to Biogen’s board — he said he incorrectly stated at first that Denner nominated her — but declined to comment on the company’s vetting process and whether it planned to disclose the relationship to shareholders before they vote on Langer’s candidacy later this month. Biogen also omitted mention of the relationship from Langer’s biography in a Securities and Exchange Commission filing Tuesday morning.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Apple is now the first public company to be valued at $3 trillion

WSS

Sports medicine is finally prioritizing gender equality

Psychedelics group wrestles with new pharma identity

Virginia high school admissions case could be legal follow

Stem cell treatment guidelines are released by FDA

Covid hospitalizations on the rise, Humana says

AstraZeneca chief proposes a novel edit to the drug pricing bill

hotspot

entertainment

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Apple is now the first public company to be valued at $3 trillion

Drug repurposing or repositioning? The language matters

Bright Health sells Medicare Advantage business to Molina

Trump demands the U.S. pay no more for drugs than other countries … again

A new House health package & hospitals’ new site

Novavax promises a turnaround & Lilly roils the obesity market

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The cancer drug shortage isn’t new — and neither are the solutions

Medicare proposal to cover medical devices draws a mixed reaction

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

'Make People Better': The CRISPR babies story you probably don't know

Supreme Court strikes down use of affirmative action

A rare thyroid diagnosis led to unexpected, all

Ethical issues complicate the benefits of medical crowdfunding

In age of alternative facts, a scholarly course on calling out crap

focus

hotspot

leisure time

focus